NCKAP1 improves patient outcome and inhibits cell growth by enhancing Rb1/p53 activation in hepatocellular carcinoma
Xiao-Ping Zhong(Shantou University), Rong Guo(Sun Yat-sen University), Wei Wei(Zhujiang Hospital), Liang-He Lu(Sun Yat-sen University), Jie Mei(Sun Yat-sen University), Shao-hua Li(Sun Yat-sen University), Yi-Hong Ling(Sun Yat-sen University), Anna Kan(Sun Yat-sen University)
Cited by 49
Related Papers
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216